The patent dispute of Daewon's anti-inflammatory drug Pelubi SR continues. Youngjin, Huons, and Chong Kun Dang won patent dispute of Pelubi. Among them, Youngjin has received generic for exclusivity alone.

According to the pharmaceutical industry on the 7th, at least three companies are considering patent challenges for Pelubi SR: Mothers Huons, and Chong Kun Dang. Although they have not filed a formal patent judgment yet, it is known that they have started developing their own generics. The industry expects the Pelubi SR patent dispute to be fiercer than the previous case of Pelubi.

This is because Pelubi SR's Rx performance is higher than that of Pelubi. According to UBIST, a pharmaceut